Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671.SS)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Hangzhou Tianmushan Pharmaceutical Enterprise receives GMP certificate
- BRIEF-Hangzhou TianMuShan Pharmaceutical Enterprise unit receives government subsidy of 36.9 mln yuan
- BRIEF-Hangzhou Tianmushan Pharmaceutical Enterprise sees FY 2017 net profit up 1,872 pct to 2,364 pct
- BRIEF-Hangzhou TianMuShan Pharmaceutical Enterprise unit obtains high-tech enterprise recognition again
- China stocks extend rally, consumer and transport firms lend support